Bruker's Q3 Revenues Climb 17 Percent

CEO Frank Laukien expressed a long-term goal of moving the company more deeply into the industrial, applied, and pharmaceutical markets and being less dependent on the academic and government market.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories